Date: 2016-04-25
Type of information: Nomination
Compound:
Company: Opko Health (USA - Fl)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 25, 2016, OPKO Health announced the appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales to support the anticipated launch of Rayaldee®, a first-in-class oral vitamin D prohormone treatment being developed for secondary hyperparathyroidism in stage 3 and 4 CKD patients with vitamin D insufficiency.
Mr. DeMarco has over 30 years of commercial pharmaceutical experience with established large companies, such as Schering Plough , Amgen and Eisai, as well as emerging companies, and a career-long focus on specialty products and nephrology. Prior to joining OPKO , Mr. DeMarco served as a consultant providing commercial leadership services to pharmaceutical, medical device and healthcare services companies. Mr. DeMarco has built a number of sales organizations during his career in advance of anticipated product launches in a diverse group of therapeutic areas.
Financial terms:
Latest news:
